Compare Citius Pharmaceuticals Inc (CTXR) vs Kohl's Corporation (KSS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Kohl's Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.73 (market cap $20.01M), while Kohl's Corporation trades at $19.2 (market cap $2.10B). The key difference: Kohl's Corporation is far larger — about 104.9× Citius Pharmaceuticals Inc's market cap, and Kohl's Corporation pays a 2.7% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | KSS | |
|---|---|---|
Market Cap | $20.01M | $2.10B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $24.71 |
52-Week Low | $0.48 | $11.72 |
Enterprise Value | $16.23M | $8.20B |
Dividend Yield | — | 2.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
Kohl's (KSS) trades at $18.96, down 0.42% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows low valuation multiples (P/E of 7.77, P/S of 0.14) amid declining revenue, which fell to $16.22B in 2025. Recent Q1 2026 earnings beat expectations, and the company announced a $0.13 dividend for June 2026, alongside leadership changes including a new COO appointment in September 2026.
The outlook is mixed: low valuations and earnings beats offer value, but persistent sales declines and thin net margins near 1.77% pose risks. Analyst consensus is cautious with a $16.75 price target below the current price, reflecting concerns over competitive pressures and cash flow volatility. Investors should weigh cost-cutting progress against macroeconomic headwinds in retail.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Kohl's Corporation
Kohl's operates 1,165 department stores in 49 states that sell moderately priced private-label and national brand clothing, shoes, accessories, cosmetics, and home furnishings. Most of these stores are in strip centers. Kohl's also operates a large digital sales business. Women's apparel is Kohl's largest category, having generated 27% of its 2021 sales. The retailer, headquartered in Menomonee Falls, Wisconsin, opened its first department store in 1962.
Read more on KSS →
